

Implanet announces the signing of a distribution agreement in Germany

Paris, December 16, 2013 – IMPLANET (Euronext: IMPL, FR0010458729), a medical technology company specializing in vertebral and knee-surgery implants, announces the signing of an exclusive distribution agreement in Germany in order to pursue, in accordance with its market plan, the expansion of its distribution network.

As a leading distributor and specialist in innovative medical devices devoted to spine surgery, the new partner has an 8-person sales team covering the whole of Germany. This partnership was finalized at the recent DWG annual meeting in Frankfurt, which brought together close to 1,100 spine surgery experts and during which the excellent reception given to JAZZ, both for scoliosis and degenerative indications, confirmed the relevance of the Company's development strategy.

With forecast annual growth of +5% over the next five years, the German vertebral fusion market, the first European market directly addressable by the Company with the JAZZ implant, is estimated at €296 million, representing 80% of the German spine surgery market¹.

"We are delighted with the finalization of this partnership with one of the German leaders in the distribution of medical products for spine surgery, the aim of which is to market new technologies that significantly reduce operating times and improve patient treatment and care. Germany has a very high level of demand for medical devices that are both top-of-the-range and beneficial to its health system. JAZZ perfectly meets these criteria through the quality of its design and its positioning as an orthopedic implant for vertebral fusion procedures, making it one of the best-reimbursed treatments on this market, a major one for Implanet", said Ludovic Lastennet, CEO of Implanet.

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. IMPLANET's proven orthopedic platform, based on perfectly controlling the traceability of its products, gives the Company the proven ability to enhance this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory approval from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 33 staff and recorded 2012 sales of €6.6 million.

For further information, please visit www.implanet.com

Contacts

IMPLANET

Tel.: +33 (0)5 57 99 55 55
investors@implanet.com

IMPL
LISTED
EURONEXT

NewCap.

Investor Relations & Financial Communication
Florent Alba / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr

¹ GBI Research Published DEC 2012 " Spinal Surgery Devices Market to 2018"